Clinical Trial Update: Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 Study

View source ↗

Summary

Post-study access for pediatric participants who completed the CSL312_3003 trial evaluating garadacimab (CSL312) for hereditary angioedema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Garadacimab (garadacimab)

Snippet

Sponsor: CSL Behring | Conditions: Hereditary Angioedema (HAE) | Status: AVAILABLE